ArticlePhysiological reviews2020
An Ounce of Prevention May Prevent Hospitalization.
Article in Physiological reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The epidemiology, pathophysiological mechanisms, and management toward COVID-19 patients with Type 2 diabetes: A systematic review.Primary care diabetes · 2021Pooled it
- The Role of SERPINE1 in Coordinating Osteogenesis and Angiogenesis of hDPSCs for Bone Regeneration.International endodontic journal · 2026Article
- Use of Tranexamic Acid in SARS-COV-2: Boon or Bane?Archives of Razi Institute · 2024Review
- Fibrinolytic system and COVID-19: From an innovative view of epithelial ion transport.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Review
- Understanding COVID-19 susceptibility and presentation based on its underlying physiology.Physiological reviews · 2022Article
- Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination.International journal of molecular sciences · 2022Review
- Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians.Pulmonary pharmacology & therapeutics · 2021Article
- Article
- Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets.Physiological reviews · 2021Review
- Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Review
- COVID-19-associated coagulopathy and disseminated intravascular coagulation.International journal of hematology · 2021Review
- Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Article
- SARS-CoV-2 and COVID-19: From the Bench to the Bedside.Physiological reviews · 2020Review
- Anti-protease Treatments Targeting Plasmin(ogen) and Neutrophil Elastase May Be Beneficial in Fighting COVID-19.Physiological reviews · 2020Article
- Consideration of Tranexamic Acid Administration to COVID-19 Patients.Physiological reviews · 2020Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.